Preferred Label : Trastuzumab;
Obsolete resource : false;
MeSH definition : A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC
AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.;
MeSH synonym : Trastuzumab beta; beta, Trastuzumab;
MeSH hyponym : herceptin; Trastuzumab-qyyp; Trastuzumab qyyp;
MeSH Related Number : 180288-69-1;
Wikipedia link : https://en.wikipedia.org/wiki/Trastuzumab;
Is substance : O;
UNII : P188ANX8CK;
Origin ID : D000068878;
UMLS CUI : C0728747;
ATC code(s)
- Allowable qualifiers
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Exact mapping(s) to DCI
- Metaterm(s)
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- ABP-980 [MeSH Supplementary Concept]
- CT-P6 [MeSH Supplementary Concept]
- Ogivri [MeSH Supplementary Concept]
- See also
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC
AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab
---
https://www.ema.europa.eu/en/medicines/human/EPAR/herwenda
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab
Trastuzumab
trastuzumab
biosimilar pharmaceuticals
---
https://www.has-sante.fr/jcms/p_3424347/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2023
false
false
false
France
Metastatic HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Antineoplastic Agents, Immunological
receptor, erbB-2
treatment outcome
insurance, health, reimbursement
adult
trastuzumab deruxtecan
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3383475/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
receptor, erbB-2
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm metastasis
Unresectable
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
Trastuzumab
breast neoplasms
trastuzumab deruxtecan
---
https://www.has-sante.fr/jcms/p_3259931/fr/phesgo
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
pertuzumab and trastuzumab
pertuzumab
Trastuzumab
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
HER2-positive metastatic or locally recurrent unresectable breast cancer,who have
not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
breast neoplasms
neoplasm metastasis
HER2 positive breast cancer
receptor, erbB-2
injections, subcutaneous
Docetaxel/Pertuzumab/Trastuzumab Regimen
evaluation of the transparency committee
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan
drug approval
europe
trastuzumab deruxtecan
Tyrosine Kinase Inhibitors
infusions, intravenous
antineoplastic agents
pregnancy
breast feeding
drug interactions
drug monitoring
adult
breast neoplasms
neoplasm metastasis
Unresectable Breast Carcinoma
aged
receptor, erbB-2
drug evaluation, preclinical
trastuzumab deruxtecan
trastuzumab deruxtecan
antineoplastic agents
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
---
https://www.has-sante.fr/jcms/p_3272596/fr/enhertu-trastuzumab-deruxtecan
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
trastuzumab deruxtecan
adult
breast neoplasms
HER2-Positive Breast Carcinoma
neoplasm metastasis
infusions, intravenous
evaluation of the transparency committee
trastuzumab deruxtecan
Trastuzumab
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
---
https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
pertuzumab
pertuzumab
drug combinations
Trastuzumab
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
pertuzumab and trastuzumab
product surveillance, postmarketing
breast neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
adult
Early-Stage HER2 Positive Breast Cancer
HER2-positive metastatic or locally recurrent unresectable breast cancer,who have
not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
receptor, erbB-2
HER-2 positive breast cancer
aged
drug interactions
pregnancy
breast feeding
ERBB2 protein, human
drug evaluation, preclinical
survival analysis
Docetaxel/Pertuzumab/Trastuzumab Regimen
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
receptor, erbB-2
---
https://www.ema.europa.eu/en/medicines/human/EPAR/zercepac
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Trastuzumab
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
biosimilar pharmaceuticals
breast neoplasms
neoplasm metastasis
stomach neoplasms
Metastatic gastric cancer
Breast cancer metastatic
Early Stage Breast Carcinoma
Early-Stage HER2 Positive Breast Cancer
HER2-positive metastatic breast cancer
HER2 positive gastric cancer
HER2 protein overexpression
receptor, erbB-2
infusions, intravenous
trastuzumab
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
---
https://www.has-sante.fr/portail/jcms/c_2969650/fr/ontruzant
2019
false
false
false
France
Trastuzumab
trastuzumab
evaluation of the transparency committee
---
https://www.has-sante.fr/portail/jcms/c_2906443/fr/ogivri
2019
false
false
false
France
treatment outcome
Trastuzumab
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
breast neoplasms
stomach neoplasms
infusions, intravenous
trastuzumab
HER2 positive gastric cancer
HER2 positive breast cancer
adult
antineoplastic combined chemotherapy protocols
neoplasm metastasis
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Trastuzumab
Trastuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
biosimilar pharmaceuticals
breast neoplasms
HER2 positive breast cancer
neoplasm metastasis
stomach neoplasms
HER2 positive gastric cancer
receptor, erbB-2
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
trastuzumab
survival analysis
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3107050/fr/ogivri
2019
false
false
false
France
Trastuzumab
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Herzuma
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Trastuzumab
Trastuzumab
antineoplastic agents
antineoplastic agents
infusions, intravenous
trastuzumab
product surveillance, postmarketing
biosimilar pharmaceuticals
antineoplastic combined chemotherapy protocols
breast neoplasms
stomach neoplasms
HER2 positive breast cancer
neoplasm metastasis
HER2 positive gastric cancer
HER2 protein overexpression
receptor, erbB-2
---
https://www.has-sante.fr/portail/jcms/c_2869241/fr/ontruzant
2018
false
France
French
Trastuzumab
biosimilar pharmaceuticals
stomach neoplasms
antineoplastic combined chemotherapy protocols
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
HER2 positive breast cancer
HER2 positive gastric cancer
Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
evaluation of the transparency committee
antineoplastic agents
treatment outcome
infusions, intravenous
receptor, erbB-2
neoplasm metastasis
breast neoplasms
trastuzumab
---
https://www.ema.europa.eu/medicines/human/EPAR/Kanjinti
2018
false
United Kingdom
French
English
syndication feed
Trastuzumab
Trastuzumab
biosimilar pharmaceuticals
europe
drug interactions
stomach neoplasms
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
HER2 positive breast cancer
HER2 positive gastric cancer
Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
antineoplastic agents
antineoplastic agents
treatment outcome
drug evaluation
infusions, intravenous
drug approval
receptor, erbB-2
neoplasm metastasis
pregnancy
breast feeding
drug storage
drug compounding
Paclitaxel/Trastuzumab Regimen
Docetaxel/Trastuzumab Regimen
HER2-positive metastatic breast cancer in patients who previously have not received
chemotherapy for metastatic disease
Early-Stage HER2 Positive Breast Cancer
TCH Regimen
Capecitabine/Trastuzumab Regimen
Cisplatin/Fluorouracil/Trastuzumab Regimen
breast neoplasms
trastuzumab
antibodies, monoclonal
package leaflet
summary of product characteristics
drug evaluation
---
https://www.ema.europa.eu/medicines/human/EPAR/Ontruzant
2018
false
United Kingdom
French
English
syndication feed
Trastuzumab
Trastuzumab
biosimilar pharmaceuticals
europe
drug interactions
stomach neoplasms
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
HER2 positive breast cancer
HER2 positive gastric cancer
Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional
release solution for injection (clinical drug)
antineoplastic agents
antineoplastic agents
treatment outcome
drug evaluation
infusions, intravenous
drug approval
receptor, erbB-2
neoplasm metastasis
pregnancy
breast feeding
drug storage
drug compounding
breast neoplasms
trastuzumab
antibodies, monoclonal
package leaflet
summary of product characteristics
drug evaluation
---
http://conseil-scientifique.public.lu/fr/publications/oncologie/trastuzumab-mise-a-jour-2018.html
2018
false
false
false
Luxembourg
French
guidelines for drug use
Trastuzumab
trastuzumab
antineoplastic agents
breast neoplasms
neoplasm metastasis
Stage IV Breast Cancer AJCC v6 and v7
HER2 positive breast cancer
receptor, erbB-2
adult
antineoplastic combined chemotherapy protocols
stomach neoplasms
Metastatic gastric adenocarcinoma
HER2 positive gastric cancer
---
https://www.ema.europa.eu/medicines/human/EPAR/Trazimera
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab
trastuzumab
drug approval
europe
treatment outcome
biosimilar pharmaceuticals
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
breast cancer
neoplasm metastasis
antineoplastic combined chemotherapy protocols
cancer of stomach
HER2 protein overexpression
infusions, intravenous
receptor, erbB-2
drug interactions
pregnancy
breast feeding
product surveillance, postmarketing
survival analysis
drug evaluation, preclinical
Trastuzumab
trastuzumab
breast neoplasms
stomach neoplasms
---
https://www.has-sante.fr/portail/jcms/c_2862565/fr/kanjinti
2018
false
France
French
Trastuzumab
Trastuzumab
biosimilar pharmaceuticals
stomach neoplasms
antineoplastic combined chemotherapy protocols
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
HER2 positive breast cancer
HER2 positive gastric cancer
evaluation of the transparency committee
antineoplastic agents
antineoplastic agents
treatment outcome
infusions, intravenous
receptor, erbB-2
neoplasm metastasis
breast neoplasms
trastuzumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2859518/fr/herzuma
2017
false
false
false
France
French
treatment outcome
Trastuzumab
antineoplastic agents
infusions, intravenous
trastuzumab
biosimilar pharmaceuticals
antineoplastic combined chemotherapy protocols
breast neoplasms
stomach neoplasms
HER2 positive breast cancer
neoplasm metastasis
HER2 positive gastric cancer
HER2 protein overexpression
receptor, erbB-2
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2637981/fr/herceptin-sein-precoce
2016
false
France
French
Trastuzumab
Trastuzumab
injections, subcutaneous
adult
survival analysis
evaluation of the transparency committee
trastuzumab
infusions, intravenous
antineoplastic agents
antineoplastic agents
genes, erbB-2
breast neoplasms
treatment outcome
antineoplastic combined chemotherapy protocols
HER2 positive breast cancer
---
http://www.has-sante.fr/portail/jcms/c_2633563/fr/herceptin-estomac
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
stomach neoplasms
Gastric Adenocarcinoma
infusions, intravenous
Trastuzumab
trastuzumab
neoplasm metastasis
adenocarcinoma
antineoplastic combined chemotherapy protocols
Gastroesophageal Junction Adenocarcinoma
Metastatic gastric cancer
Trastuzumab
stomach neoplasms
genes, erbB-2
---
http://www.has-sante.fr/portail/jcms/c_2620144/fr/herceptin
http://www.has-sante.fr/portail/jcms/c_1739160/fr/herceptin
2016
false
false
false
France
French
English
evaluation of the transparency committee
guidelines for drug use
injections, subcutaneous
treatment outcome
trastuzumab
breast neoplasms
neoplasm metastasis
receptor, erbB-2
HER2 positive breast cancer
continuity of patient care
adult
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
Trastuzumab
Trastuzumab
infusions, intravenous
Stage IV Breast Cancer AJCC v6 and v7
---
https://www.jle.com/fr/revues/jpc/e-docs/biotherapies_ciblees_dans_le_cancer_du_sein_mise_a_jour_des_connaissances_et_nouvelles_donnees_2014_2015_305540/article.phtml
https://www.jle.com/fr/revues/jpc/e-docs/biotherapies_ciblees_dans_le_cancer_du_sein_mise_a_jour_des_connaissances_et_nouvelles_donnees_2014_2015_305540/article.phtml?tab=download&pj_key=doc_attach_28913
2015
false
false
false
France
French
review of literature
breast neoplasms
antineoplastic agents
treatment outcome
neoplasm metastasis
injections, subcutaneous
patient preference
Bevacizumab
Trastuzumab
---
http://www.has-sante.fr/portail/jcms/c_1756827/fr/tyverb
2014
false
France
French
guidelines for drug use
Trastuzumab
evaluation of the transparency committee
quinazolines
antineoplastic agents
protein kinase inhibitors
insurance, health, reimbursement
administration, oral
lapatinib
breast neoplasms
neoplasm metastasis
antineoplastic combined chemotherapy protocols
receptor, erbB-2
adult
aged
treatment outcome
antineoplastic agents
quinazolines
protein kinase inhibitors
lapatinib ditosylate
lapatinib ditosylate
HER2 positive breast cancer
Lapatinib
Lapatinib
---
http://www.cochrane.org/fr/CD006242/efficacite-et-innocuite-du-trastuzumab-dans-le-cancer-du-sein-metastatique
2014
false
false
false
France
United Kingdom
French
french abstract
treatment outcome
antineoplastic agents
breast neoplasms
neoplasm metastasis
Human epidermal growth factor 2 positive carcinoma of breast (disorder)
ERBB2 protein, human
antineoplastic agents
review of literature
Trastuzumab
Trastuzumab
breast neoplasms
receptor, erbB-2
---
http://www.has-sante.fr/portail/jcms/c_1359733/herceptin
http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/herceptin_neoadjuvant_avis2_ct12365.pdf
2013
false
France
French
Trastuzumab
Trastuzumab
evaluation of the transparency committee
trastuzumab
infusions, intravenous
antineoplastic agents
antineoplastic agents
genes, erbB-2
breast neoplasms
clinical trials, phase iii as topic
treatment outcome
survival analysis
antineoplastic combined chemotherapy protocols
HER2 positive breast cancer
---
https://www.ema.europa.eu/medicines/human/EPAR/Herceptin
2012
false
United Kingdom
French
English
injections, subcutaneous
syndication feed
Trastuzumab
Trastuzumab
antineoplastic agents
antineoplastic agents
treatment outcome
drug evaluation
infusions, intravenous
drug approval
drug labeling
receptor, erbB-2
neoplasm metastasis
pregnancy
breast feeding
drug storage
drug compounding
breast neoplasms
trastuzumab
antibodies, monoclonal
HER2 positive breast cancer
package leaflet
summary of product characteristics
drug evaluation
---
http://www.cochrane.org/fr/CD006243
2012
false
true
false
United Kingdom
France
Trastuzumab
treatment outcome
secondary prevention
review of literature
french abstract
breast neoplasms
---
http://www.has-sante.fr/portail/jcms/c_1061968/herceptin-trastuzumab-anticorps-monoclonal-synthese-d-avis
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-03/herceptin_-_ct-9411.pdf
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Trastuzumab
Trastuzumab
trastuzumab
stomach neoplasms
neoplasm metastasis
antineoplastic agents
infusions, intravenous
treatment outcome
antineoplastic agents
---
http://www.has-sante.fr/portail/jcms/c_1036288/herceptin
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-03/herceptin_-_ct-9411.pdf
2011
false
France
French
Trastuzumab
infusions, intravenous
trastuzumab
antineoplastic agents
stomach neoplasms
neoplasm metastasis
treatment outcome
genes, erbB-2
evaluation of the transparency committee
---
https://www.inspq.qc.ca/sites/default/files/publications/1147_rapportcepo.pdf
2010
false
Canada
French
Trastuzumab
guideline adherence
practice guidelines as topic
breast neoplasms
breast neoplasms
receptor, erbB-2
health surveys
questionnaires
---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/14050a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2009/14552a-fra.php
2009
false
Canada
French
English
Trastuzumab
pregnancy
pregnancy trimester, second
pregnancy trimester, third
antineoplastic agents
receptor, erbB-2
breast neoplasms
oligohydramnios
pharmacovigilance note
popular works
---
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_analyseii_20090604.pdf
2009
Canada
drug information
trastuzumab
Trastuzumab
Adjuvant
Male Breast Carcinoma
breast cancer
Additive
Adjuvant Therapy Clinical Trial Setting
Childhood Breast Carcinoma
breast neoplasms
neoplasm, malignant
adjuvant, nos
Adjudicator
Trastuzumab
---
http://www.msss.gouv.qc.ca/sujets/organisation/lutte-contre-le-cancer/documents/guides-cepo-pdf/CEPO-Trastuzumab_et_traitement_adjuvant_du_cancer_du_sein-_mise_%C3%A0_jour_(2008-02).pdf
2008
false
false
Canada
French
Trastuzumab
receptor, erbB-2
breast neoplasms
neoadjuvant therapy
treatment outcome
survival rate
antineoplastic agents
breast neoplasms
Evidence-Based medicine
bibliography of medicine
quebec
trastuzumab
guidelines for drug use
HER2 positive breast cancer
---
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_seinadjuvant_ad_et_rum_20070515.pdf
2007
Canada
drug information
Childhood Breast Carcinoma
neoplasm, malignant
Additive
trastuzumab
Trastuzumab
Adjuvant Therapy Clinical Trial Setting
adjuvant, nos
Trastuzumab
Male Breast Carcinoma
Adjuvant
breast cancer
Adjudicator
breast neoplasms
---
https://rmlg.uliege.be/article/1650
2007
false
Belgium
French
Trastuzumab
Bevacizumab
angiogenesis inhibitors
receptor, erbB-2
antineoplastic agents
breast neoplasms
journal article
HER2 positive breast cancer
---
https://www.minerva-ebp.be/fr/article/669
2006
false
false
minerva-ebm.be
Belgium
French
Trastuzumab
Trastuzumab
breast neoplasms
antineoplastic agents
receptor, erbB-2
combined modality therapy
treatment outcome
antineoplastic agents
breast neoplasms
breast neoplasms
chemotherapy, adjuvant
critical appraisal or critical reading
HER2 positive breast cancer
---
http://kce.fgov.be/fr/publication/report/trastuzumab-pour-les-stades-pr%C3%A9coces-du-cancer-du-sein
2006
false
Belgium
French
English
Trastuzumab
Trastuzumab
Trastuzumab
breast neoplasms
receptor, erbB-2
Cost-Benefit analysis
breast neoplasms
belgium
neoplasm recurrence, local
evaluation studies
public health guidelines
---
https://pgtmsite.files.wordpress.com/2024/01/trastuzumab_seinadjuvant_pgtm_20051004.pdf
2005
Canada
drug information
breast neoplasms
Childhood Breast Carcinoma
adjuvant, nos
Adjuvant Therapy Clinical Trial Setting
breast cancer
Adjuvant
neoplasm, malignant
trastuzumab
Trastuzumab
Trastuzumab
Adjudicator
Additive
Male Breast Carcinoma
---
http://www.has-sante.fr/portail/display.jsp?id=c_246948
2005
false
France
French
Trastuzumab
breast neoplasms
receptor, erbB-2
antineoplastic agents
trastuzumab
evaluation of the transparency committee
---
http://www.msss.gouv.qc.ca/sujets/organisation/lutte-contre-le-cancer/documents/guides-cepo-pdf/CEPO-Trastuzumab_et_traitement_adjuvant_du_cancer_du_sein-_mise_%C3%A0_jour_(2008-02).pdf
2005
false
false
Canada
French
Trastuzumab
Trastuzumab
antineoplastic agents
breast neoplasms
quebec
breast neoplasms
survival rate
chemotherapy, adjuvant
antineoplastic agents
neoplasm staging
antineoplastic combined chemotherapy protocols
receptor, erbB-2
trastuzumab
guidelines for drug use
---
https://www.cadth.ca/sites/default/files/pdf/218_No26_herceptin_preassess_e.pdf
https://www.cadth.ca/sites/default/files/pdf/218_No26_herceptin_preassess_f.pdf
2003
false
Canada
French
English
Trastuzumab
Trastuzumab
antineoplastic agents
antineoplastic agents
receptor, erbB-2
breast neoplasms
time factors
treatment outcome
Evidence-Based medicine
canada
controlled clinical trials as topic
trastuzumab
risk assessment
drug evaluation
---
https://www.cadth.ca/sites/default/files/pdf/ews4_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/ews4_cetap_e.pdf
1999
false
Canada
French
English
Trastuzumab
infusions, intravenous
antineoplastic agents
breast neoplasms
neoplasm metastasis
receptor, erbB-2
treatment outcome
canada
survival rate
clinical trials as topic
trastuzumab
drug evaluation
---
